NovaBay Pharma (NBY) Misses Q4 EPS by 2c
Tweet
Share
E-mailGet Alerts NBY Hot Sheet
Price: $0.07 --0%
EPS Growth %: -270.0%
Financial Fact:
Other revenues: 176K
Today's EPS Names:
SFST, VLTO, CLIR, More
EPS Growth %: -270.0%
Financial Fact:
Other revenues: 176K
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
NovaBay Pharma (NYSE: NBY) reported Q4 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $385 thousand versus the consensus estimate of $60 thousand.
For earnings history and earnings-related data on NovaBay Pharma (NBY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
- Spotify (SPOT) jumps 10% as Q1 revenue, gross margins beat Street's estimates
- Philip Morris (PM) beats Q1 earnings, revenue estimates; issues upbeat guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
